CASP8 and FADD like apoptosis regulatorGenealiases: CASH · CASP8AP1 · CLARP · Casper · FLAME · FLAME-1
Q-omics provides the consensus-scored CFLAR profile across patient tissues and cancer cell-line models. CFLAR expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CFLAR is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, CFLAR RNA expression shows 21,173 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KIRC, and UVM as cancer lineages where CFLAR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CFLAR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CFLAR survival associations across molecular data types. CFLAR RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CFLAR RNA expression–survival associations across cancer types. High CFLAR expression shows unfavorable associations in ACC, LGG and UVM, but favorable associations in HNSC, SKCM and SARC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CFLAR RNA expression.
This table summarizes CFLAR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CFLAR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CFLAR shows lower tumor expression in KICH, LUSC, LUAD and BRCA and higher tumor expression in KIRC and LIHC. The KIRC box plot shows higher CFLAR RNA expression in tumor versus normal tissue (log2 FC = +0.581, t-test p < 0.001).
This table shows molecular features associated with CFLAR in patient tissues and cancer cell lines. In patient samples, CFLAR shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CFLAR RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
